For researchers and biomedical laboratories focused on neuroscience, neurodegenerative disease studies, or neural injury research, the Human/Mouse/Rat NFL One-Step ELISA Kit from Antbio Inc. emerges as a cutting-edge and versatile tool. This specialized kit is meticulously designed to enable rapid, accurate, and simultaneous detection of Neurofilament Light Chain (NFL) in human, mouse, and rat samples—eliminating the need for multiple species-specific kits and streamlining experimental workflows.
Crafted with precision, the kit integrates a one-step assay format that reduces hands-on time while upholding exceptional sensitivity and specificity. It includes all critical components (pre-coated microplates, optimized reagents, standard solutions, etc.) to ensure consistent, reproducible results across different operators and laboratory environments. Whether analyzing biological fluids (such as cerebrospinal fluid, serum, or plasma) or cell lysates, the kit delivers reliable NFL quantification, making it ideal for basic research, preclinical studies, and translational research applications related to neural health and disease.
Backed by Antbio Inc.’s commitment to manufacturing high-quality immunoassay products, this NFL One-Step ELISA Kit adheres to strict quality control standards, guaranteeing batch-to-batch consistency and trustworthy performance. To explore detailed product specifications, technical documents, pricing, and ordering options, visit the official product page: Human/Mouse/Rat NFL One-Step ELISA Kit | Antbio Inc.
| Antigen |
NFL |
| Immunogen |
Recombinant Protein |
| Antibody Type |
Recombinant mAb |
| Reactivity |
Hu, Ms, Rt |
| Purification |
Protein A |
| Stability & Storage |
2 to 8 ℃ as supplied.
|
The Neurofilament Light Chain (NfL), a ~68 kDa protein encoded by the NEFL gene, is a critical structural component of the neuronal cytoskeleton, predominantly expressed in large myelinated axons of the central and peripheral nervous systems. As part of the neurofilament family (including NfM and NfH chains), NfL forms heteropolymers that stabilize axonal structure, regulate axon diameter to modulate nerve conduction velocity, and facilitate intracellular transport by acting as a scaffold for organelles and signaling molecules. Its release into biofluids (e.g., cerebrospinal fluid and blood) following neuronal injury or degeneration has established NfL as a highly sensitive, disease-agnostic biomarker of neuroaxonal damage. Elevated NfL levels correlate with diverse neurological conditions, including neurodegenerative diseases (Alzheimer's, Parkinson's, ALS), neuroinflammatory disorders (multiple sclerosis, neuromyelitis optica), stroke, and traumatic brain injury. Notably, NfL rises before clinical symptoms emerge, enabling early detection, while baseline concentrations predict disease progression and outcomes. Reductions in NfL levels are increasingly used to monitor therapeutic efficacy in clinical trials, such as antisense oligonucleotide therapies for ALS. Ultrasensitive assays like Simoa allow noninvasive blood-based quantification, enhancing its utility for longitudinal monitoring. With high sensitivity, accessibility, and broad applicability, NfL has become pivotal in advancing diagnostics, prognostics, and personalized treatment strategies for neurological disorders.
中文
